The current invention is down to (+) an (-) enantiomers, as well as racemic mixtures of nucleoside analogs, wherein the carbohydrate portion of the analog is a dioxolane moiety and the nucleobase moiety is N.sup.6 -carbocyclic-alkylamino-substituted-2-amino-purine moiety attached via its N.sup.9 position to the dioxolane moiety. The compounds are useful for treating viral infections such as HBV and HIV infections, alone or in combination with other therapeutic agents.

The invention relates to cis-nucleosides of formula (I): ##STR1## and pharmaceutically acceptable salts thereof, wherein X, R.sub.3, R.sub.4 and are as defined herein. The nucleosides can be in racemic form or in the form of their (+) or (-) enantiomers. The compounds are useful for treating HBV and/or HIV infections, alone or in combination with other therapeutic agents.

Methods and compositions for preventing or treating human immunodeficiency virus (HIV) infections characterized by 2-substituted-5-substituted-1,3-oxathiolanes.

Methods and compositions for preventing or treating human immunodeficiency virus (HIV) infections characterized by 2-substituted-5-substituted-1,3-oxathiolanes.

The present invention relates to a novel nucleotide analogue having the general formula (I) and pharmaceutically acceptable salts, esters, or salt of such esters: ##STR1## wherein n, X, Q U R1', R1, Z and R.sub.2 are defined here within. The compounds object of the present invention may be a single enantiomers or as mixtures of said enantiomers, the compounds may have a .alpha.D, .alpha.-L, .beta.-D, .beta.-L, R or S configuration at each chiral center or mixtures thereof. This invention also re...

There is provided novel 2-substituted-4-substituted-1,3-dioxolanes which are particularly useful as antiviral agents.

There are provided novel 2-substituted-4-substituted-1,3-dioxolanes which are particularly useful as antiviral agents.

The present invention relates to the use of nucleoside analogues in the treatment of viral infections. More specifically it is concerned with the use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis, in particular hepatitis B.

Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed. ##STR1##

The present invention is concerned with novel [1,8] naphthyridine derivatives useful for the inhibition of the hepatitis virus, more specifically the hepatitis C virus.